What does it help with
Long-Term Safety Considerations As a relatively new class of medications, the long-term safety profile of GLP-1 agonists is still under evaluation
Changes in levels of plasma DPP-4 activity could, therefore, be related to overall changes in the total expression of DPP-4 and/or simply altered shedding from cell membranes
Recalls & Warnings July 01, 2003 Direct Marketers of Weight Loss, Impotence, and Arthritis Supplements Charged with Deceptive Claims On July 1, 2003, the Federal Trade Commission (FTC) announced three enforcement actions against direct marketers of weight-loss products containing ephedra
In January of 2025, Ozempic was also approved to reduce the risk of kidney disease progression, kidney failure, and death from cardiovascular disease in individuals with chronic kidney disease and type 2 diabetes